# Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan

> **NCT02251613** · PHASE4 · COMPLETED · sponsor: **Alcon Research** · enrollment: 50 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Olopatadine HCl ophthalmic solution, 0.1%
- **DRUG:** Epinastine HCl ophthalmic solution, 0.05%

## Key facts

- **NCT ID:** NCT02251613
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2015-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251613, "Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02251613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*